Company Overview and News

 
BT journalists win accolades at Sias awards

2018-09-26 businesstimes.com.sg
THE Business Times' Angela Tan has topped this year's financial journalism honours at the Securities Investors' Association of Singapore's (Sias) Investors' Choice Awards 2018.
VARHF SGPRY ACNDY PDMXY YLWWF YLWDF ACNDF CPAMF CY6U DMPLF SGPRF DMPL Y D03

 
Del Monte Pacific Ltd. ADR 2019 Q1 - Results - Earnings Call Slides

2018-09-14 seekingalpha
The following slide deck was published by Del Monte Pacific Ltd. ADR in conjunction with their 2019 Q1 earnings call.
DMPLF PDMXY DMPL D03

 
Del Monte Pacific reports higher 1Q earnings of US$3 mil on one-off gain

2018-09-13 theedgemarkets
SINGAPORE (Sept 12): Del Monte Pacific reported a 1Q19 earnings of US$3 million (S$4.1 million). This is higher than US$0.7 million in 1Q18 and was the result of a one-off gain from the purchase of DMFI loans.
DMPLF DMPL PDMXY D03

24
Pass Me A LaCroix: How Specialty Sodas Are Disrupting The Beverage Industry

2018-07-27 valuewalkpremium - 3
In our “Trending Foods” series of blog posts, we analyzed interesting trends in the food industry, such as the increasing popularity of protein-rich grains, the avocado craze, and the changing customer habits that are fueling new consumption patterns, such as the brunch and street food phenomenon.
SODA TRUU DMPLF DMPL KO PDMXY FIZZ D03

1
Del Monte Pacific reports FY18 net loss of US$28 mil on one-off closure expenses

2018-07-27 theedgemarkets - 1
SINGAPORE (July 27): Del Monte Pacific reported a net loss of US$28.2 million (S$38.4 million) in FY2018, versus earnings of US$24.4 million in FY2017.
DMPLF DMPL PDMXY D03

 
Expansion of ASEAN food corporations

2018-07-16 bworldonline
Many Philippine companies expand overseas to reach more consumers and increase revenues. Also, companies can utilize global markets to introduce unique products and services (https://www.bizjournals.com/).
SMCP1 UNITDSPR JBFCY PDMXY UVRBY RI SMGBY SMGBF 532432 SMC2B SMC2A JBFCF SMC SMC2D SMC2C SMC2F JFC DMPLF URC SMC2E UQNTY DMPL D03 UVRBF

1
Del Monte Pacific Ltd. ADR 2018 Q4 - Results - Earnings Call Slides

2018-06-29 seekingalpha
The following slide deck was published by Del Monte Pacific Ltd. ADR in conjunction with their 2018 Q4 earnings call.
DMPLF PDMXY DMPL D03

1
Del Monte suffers net loss thanks to plant closures

2018-06-29 bworldonline
DEL MONTE Pacific Limited (DMPL) swung to a net loss for the fiscal year ending April 2018, dragged by the closure of two plants in the United States.
DMPLF DMPL PDMXY D03

1
Del Monte Pacific reports net loss due to closure of two US plants

2018-06-29 bworldonline
Del Monte Pacific Limited (DMPL) swung to a net loss for the fiscal year ending April 2018, dragged by the closure of two plants in the United States.
DMPLF DMPL PDMXY D03

1
Del Monte Pacific 4Q earnings surge on one-off but FY18 still ends with US$28m loss

2018-06-29 theedgemarkets
SINGAPORE (June 29): Del Monte Pacific (DMPL), the producer of branded fruits and vegetable, juices and condiments, reported 4Q earnings ended April of US$12.3 million (S$16.8 million), four times higher than the US$2.9 million in the same quarter last year.
DMPLF DMPL PDMXY D03

6
Del Monte Philippines books P2.6-B profit

2018-06-20 bworldonline
DEL MONTE Philippines, Inc. (DMPI)’s net income was flat for its fiscal year ending April 2018, due to higher interest expenses amid a single-digit growth in sales.
PSKXF DMPLF DMPL PHSXY PDMXY PSE D03

7
Del Monte Philippines defers IPO

2018-06-08 bworldonline - 1
DEL MONTE Philippines, Inc. (DMPI) has delayed what would have been the country’s first initial public offering this year, citing the current volatility in the local stock market.
PSKXF DMPLF DMPL PHSXY PDMXY PSE D03

6
Del Monte Philippines defers IPO

2018-06-07 business.inquirer.net
Food producer Del Monte Philippines Inc. has deferred its P17.55-billion initial public offering, citing turbulent market conditions.
PSKXF DMPLF DMPL PHSXY PDMXY PSE D03

1
Del Monte PHL’s IPO gets PSE go-ahead

2018-05-31 bworldonline
THE Philippine Stock Exchange has given the greenlight for the P17.5-billion initial public offering (IPO) of Del Monte Philippines, Inc. (DMPI) on Thursday.
DMPLF DMPL PDMXY D03

6
PSE approves Del Monte Philippines’ P17.5-billion IPO

2018-05-31 bworldonline
The Philippine Stock Exchange has given the greenlight for the P17.5-billion initial public offering (IPO) of Del Monte Philippines, Inc. (DMPI) on Thursday.
PSKXF DMPLF DMPL PHSXY PDMXY PSE D03

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...